Metolar Trio 25 Tablet ER is a combination antihypertensive medication containing Cilnidipine (10 mg), Metoprolol Succinate (25 mg), and Telmisartan (40 mg). This extended-release formulation is designed to provide sustained blood pressure control in patients with hypertension. Cilnidipine, a calcium channel blocker, inhibits L- and N-type calcium channels, leading to vasodilation and reduced peripheral resistance. Metoprolol Succinate, a selective beta-1 adrenergic receptor blocker, decreases heart rate and myocardial contractility, thereby reducing cardiac output. Telmisartan, an angiotensin II receptor blocker (ARB), prevents vasoconstriction and aldosterone secretion by selectively blocking the AT1 receptor, promoting vasodilation and sodium excretion. The synergistic action of these three agents targets multiple pathways involved in blood pressure regulation, enhancing therapeutic efficacy and minimizing adverse effects compared to monotherapy. Metolar Trio 25 Tablet ER is indicated for the management of essential hypertension, particularly in patients requiring combination therapy for optimal blood pressure control. It should be used under medical supervision with regular monitoring of blood pressure, renal function, and electrolytes. Contraindications include hypersensitivity to any component, severe hepatic impairment, and pregnancy. Adverse effects may include dizziness, fatigue, hypotension, and mild gastrointestinal disturbances.